COPD hero image

Chronic Obstructive Pulmonary Disease (COPD) is a common, treatable chronic lung disease that causes obstructed airflow from the lungs.

Untreated, COPD can lead to a fast progression of disease, heart problems, and worsening respiratory infections. However, with the right diagnosis and treatment, patients may breathe better, enjoy life and live for many years.

What treatments do GSK offer for patients with COPD?

Pack shot

Anoro Ellipta (umeclidinium/vilanterol) is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

Pack shot

Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol) is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LAMA and a LABA.

Get Started

References

  1. National Institute for Health and Care Excellence, COPD 2019. Available at https://cks.nice.org.uk/chronic-obstructive-pulmonary-disease#!backgroundSub:1 [Accessed May 2022].
  2. ONS, Deaths from asthma and COPD, England & Wales, 2001 to 2017 https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/adhocs/009602deathsfromasthmaandcopdenglandandwales2001to2017byoccurrence (Accessed May 2022)

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.

Trademarks are the property of their respective owners Trelegy Ellipta and Anoro Ellipta were developed in collaboration with INNOVIVA

Innoviva logo

June 2022 | PM-GB-UCV-WCNT-200004 (V2.0)